OPK: OPKO Corp Kapitalizatsiyaning foydaga nisbati

OPKO Corp - OPK emitenti grafik logotipi

OPKO Health, Inc. (OPK) kompaniyasining samaradorlik o'sishi laboratoriya avtomatlashtiruvi va patent daromadlariga asoslangan. Emitentning P/E koeffitsiyenti ushbu tendentsiyani aks ettiradi va joriy parametr -8.10 darajasida turibdi. Barqarorlik farmatsevtika ishlanmalari va diagnostikaning kombinatsiyasi orqali ta'minlanadi. Biroq, bozordagi shiddatli raqobat kompaniyani daromadlilikni saqlab qolish va biznes tuzilmasini optimallashtirish uchun noyob testlarni joriy etishga majbur qilmoqda.

OPKO Health (OPK) P/E multiplikatori: 04.07.2022 - 13.11.2026 davri uchun

OPKO Health, Inc. kompaniyasining tahliliy kesimlari

- kotirovkalar va tahlilchilar prognozi:
Kompaniyaning har tomonlama tahlili:opko.com (OPK)
OPKO Health ishlab chiqargan mahsulot

P/E koeffitsiyenti foydaning bir birligi uchun xarajatni belgilaydi, bu esa investorga aktivning sof daromad keltirish qobiliyatiga nisbatan haddan tashqari to'lov miqdorini baholash imkonini beradi. OPKO Health, Inc. (OPK) kompaniyasining P/E dinamikasini tahlil qilish orqali uning diagnostika laboratoriyalarining kengayish imkoniyatlari va yuqori marjali patent royalti to'lovlari biznesning bozor qiymatiga qanday ta'sir qilishini tushunish mumkin, bu esa uning operatsion richagi samaradorligini tasdiqlaydi.

Raqobatdosh kompaniyalar tahlili

Narxning foydaga nisbati A|Narx-foyda koeffitsiyenti DGX (Quest Diagnostics Incorporated)|ILMN - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Cologuard EXAS|Biznesning o‘zini qoplash muddati Revvity Corp (RVTY)|Bio-Rad Laboratories - P/E multiplikatori|Biznesning o‘zini qoplash muddati anbio.com NNNN|Sotera Health (SHC) - Narxning foydaga nisbati|QDEL - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati CareDx, Inc|Kapitalizatsiyaning foydaga nisbati Maravai MRVI|Narxning foydaga nisbati Fulgent Genetics, Inc. (FLGT)|LAB: Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Cytek Biosciences CTKB|P/E multiplikatori OraSure Technologies, Inc. OSUR|XGN - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati MDxHealth, Inc.|LUCD (Lucid Diagnostics Inc.) - Narx-foyda koeffitsiyenti|Prenetics - Kompaniya qiymatining sof foydaga nisbati|IMDX (Insight Molecular Diagnostics, Inc.) - P/E multiplikatori|TRIB: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori PRPH|AIMD - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori CODX (Co-Diagnostics, Inc.)|P/E multiplikatori heartsciences.com HSCS|BMRA - Narxning foydaga nisbati|CDIO: Narxning foydaga nisbati|ONCO (Onconetix Corp) - Narx-foyda koeffitsiyenti|VRAX: Bozor narxining sof foydaga nisbati|BJDX (Bluejay Diagnostics) - P/E multiplikatori|AWH: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti AXDX (Accelerate Diagnostics, Inc.)|CNTG (CENTOGENE) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ENZ (Enzo Biochem)|Biznesning o‘zini qoplash muddati Fresh2 Group Ltd (FRES)|GENE - Narxning foydaga nisbati|ME (23andme.com) - Narx-foyda multiplikatori|PMD: P/E multiplikatori